{"entity":{"id":"nct03667170","kind":"trial","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","summary":"KN035 for dMMR/MSI-H Advanced Solid Tumors is a phase 2 interventional study registered as NCT03667170 by 3D Medicines (Sichuan) Co., Ltd., with 200 participants planned, started 2018-08-22 and due to reach its primary completion in 2026-12-30. Interventions recorded: KN035.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03667170","url":"https://clinicaltrials.gov/study/NCT03667170"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["envafolimab"],"companies":["3d-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03667170","phase":"2","setting":"Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors","sponsor":"3D Medicines (Sichuan) Co., Ltd.","started":"2018-08-22","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03667170/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"}],"company":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/"}]}}